Phosphorylation of NHERF1 S279 and S301 differentially regulates breast cancer cell phenotype and metastatic organotropism.


Journal

Biochimica et biophysica acta. Molecular basis of disease
ISSN: 1879-260X
Titre abrégé: Biochim Biophys Acta Mol Basis Dis
Pays: Netherlands
ID NLM: 101731730

Informations de publication

Date de publication:
01 2019
Historique:
received: 15 05 2018
revised: 21 09 2018
accepted: 11 10 2018
pubmed: 17 10 2018
medline: 14 8 2019
entrez: 17 10 2018
Statut: ppublish

Résumé

Metastatic cancer cells are highly plastic for the expression of different tumor phenotype hallmarks and organotropism. This plasticity is highly regulated but the dynamics of the signaling processes orchestrating the shift from one cell phenotype and metastatic organ pattern to another are still largely unknown. The scaffolding protein NHERF1 has been shown to regulate the expression of different neoplastic phenotypes through its PDZ domains, which forms the mechanistic basis for metastatic organotropism. This reprogramming activity was postulated to be dependent on its differential phosphorylation patterns. Here, we show that NHERF1 phosphorylation on S279/S301 dictates several tumor phenotypes such as in vivo invasion, NHE1-mediated matrix digestion, growth and vasculogenic mimicry. Remarkably, injecting mice with cells having differential NHERF1 expression and phosphorylation drove a shift from the predominantly lung colonization (WT NHERF1) to predominately bone colonization (double S279A/S301A mutant), indicating that NHERF1 phosphorylation also acts as a signaling switch in metastatic organotropism.

Identifiants

pubmed: 30326259
pii: S0925-4439(18)30394-6
doi: 10.1016/j.bbadis.2018.10.017
pii:
doi:

Substances chimiques

Mutant Proteins 0
Phosphoproteins 0
Slc9a1 protein, mouse 0
Sodium-Hydrogen Exchanger 1 0
Sodium-Hydrogen Exchangers 0
sodium-hydrogen exchanger regulatory factor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

26-37

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Maria Raffaella Greco (MR)

Department of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Italy.

Emeline Bon (E)

Université de Tours, Inserm UMR1069, Nutrition, Croissance et Cancer, Tours, France.

Rosa Rubino (R)

Department of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Italy.

Lorenzo Guerra (L)

Department of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Italy.

Manuel Bernabe-Garcia (M)

Telomerase, Cancer and Aging Group, Research Unit, Department of Surgery, CIBERehd - University Hospital "Virgen de la Arrixaca", Murcia, Spain.

Stefania Cannone (S)

Department of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Italy.

Maria-Luisa Cayuela (ML)

Telomerase, Cancer and Aging Group, Research Unit, Department of Surgery, CIBERehd - University Hospital "Virgen de la Arrixaca", Murcia, Spain.

Loredana Ciaccia (L)

Department of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Italy.

Séverine Marionneau-Lambot (S)

Cancéropôle du Grand Ouest, Nantes, France.

Thibauld Oullier (T)

Cancéropôle du Grand Ouest, Nantes, France.

Gaëlle Fromont (G)

Université de Tours, Inserm UMR1069, Nutrition, Croissance et Cancer, Tours, France; Centre Hospitalo-Universitaire de Tours, Tours, France.

Roseline Guibon (R)

Université de Tours, Inserm UMR1069, Nutrition, Croissance et Cancer, Tours, France; Centre Hospitalo-Universitaire de Tours, Tours, France.

Sébastien Roger (S)

Université de Tours, Inserm UMR1069, Nutrition, Croissance et Cancer, Tours, France; Institut Universitaire de France, Paris, France. Electronic address: sebastien.roger@univ-tours.fr.

Stephan Joel Reshkin (SJ)

Department of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Italy. Electronic address: stephanjoel.reshkin@uniba.it.

Rosa Angela Cardone (RA)

Department of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH